ArticleMicrobiology spectrum2026
Genetic variation, recombinant characteristics, and seroprevalence analysis of echovirus 3 causing severe and mild cases of hand, foot, and mouth disease in Guizhou Province.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Echovirus 3 (E-3) has recently been identified as an emerging pathogen associated with both severe and mild cases of hand, foot, and mouth disease (HFMD) in Guizhou Province, China. Although these strains exhibit distinct clinical phenotypes, their underlying molecular mechanisms remain unclear. This study reports the phylogenetic and genetic features of eight E-3 strains from severe and mild HFMD cases and investigates E-3 seroprevalence in Guizhou. Eight shared nucleotide substitutions in the untranslated regions (UTRs) and six shared amino acid substitutions in the open reading frame (ORF) were identified between E-3 strains from severe and mild case groups. Nine variant-specific amino acid mutations were under positive selection and exhibited high variability. Among the 115 nucleotide substitutions in the ORF regions, 31 were specific to the severe case group and 41 to the mild case group. Recombination analysis revealed that the Guizhou E-3 strains underwent complex interserotypic recombination with echovirus 21 (E-21), enterovirus B80 (EV-B80), and echovirus 30 (E-30). E-3 strains from the severe case group demonstrated enhanced replication efficiency, higher viral titers, and greater cytopathogenicity than those from the mild case group. Analysis of 178 samples revealed a seropositivity rate of 52.25% and a geometric mean titer (GMT) of 1:28.23 for E-3, indicating the prevalence of asymptomatic infections in Guizhou Province. All Guizhou E-3 strains exhibited non-temperature-sensitive characteristics, suggesting their potential for transmissibility within the population. This study provides valuable insights for global studies on E-3-related diseases and molecular epidemiology, establishing a foundation for further investigation into the pathogenicity of E-3 variants.IMPORTANCEThis study is the first report of echovirus 3 (E-3) infections associated with severe hand, foot, and mouth disease (HFMD) cases in Guizhou Province, China. All E-3 strains showed thermotolerance and higher seroprevalence, suggesting potentially enhanced transmissibility. Several shared nucleotide substitutions and amino acid substitutions were identified in Guizhou strains from both severe and mild case groups, indicating that E-3 may have evolved through continuous genetic adaptation, potentially driving the emergence of more transmissible epidemic variants. This study revealed that the E-3 strains in the severe case group exhibited enhanced replication efficiency, higher viral titers, and increased cytopathogenicity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.